Cargando…
Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of anti-diabetic drugs. They control both fasting and postprandial hyperglycemia by inhibiting degradation of incretin hormones, such as, glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Sitagliptin is th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544143/ https://www.ncbi.nlm.nih.gov/pubmed/26312005 http://dx.doi.org/10.4103/0976-500X.162016 |
_version_ | 1782386649103073280 |
---|---|
author | Sahoo, Jayaprakash Kamalanathan, Sadishkumar Vivekanandan, Muthupillai Swaminathan, Rathinam Palamalai |
author_facet | Sahoo, Jayaprakash Kamalanathan, Sadishkumar Vivekanandan, Muthupillai Swaminathan, Rathinam Palamalai |
author_sort | Sahoo, Jayaprakash |
collection | PubMed |
description | Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of anti-diabetic drugs. They control both fasting and postprandial hyperglycemia by inhibiting degradation of incretin hormones, such as, glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Sitagliptin is the first DPP-4 inhibitor to be marketed in India. In addition to its glucose lowering effect, it also suppresses immunity resulting in various infections in a diabetes patient. Here, we describe the simultaneous development of two infections (acalculous pyelonephritis and cholecystitis) in a postmenopausal female patient, well-controlled on sitagliptin-based anti-diabetic therapy. |
format | Online Article Text |
id | pubmed-4544143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-45441432015-08-26 Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy Sahoo, Jayaprakash Kamalanathan, Sadishkumar Vivekanandan, Muthupillai Swaminathan, Rathinam Palamalai J Pharmacol Pharmacother Case Report Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of anti-diabetic drugs. They control both fasting and postprandial hyperglycemia by inhibiting degradation of incretin hormones, such as, glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Sitagliptin is the first DPP-4 inhibitor to be marketed in India. In addition to its glucose lowering effect, it also suppresses immunity resulting in various infections in a diabetes patient. Here, we describe the simultaneous development of two infections (acalculous pyelonephritis and cholecystitis) in a postmenopausal female patient, well-controlled on sitagliptin-based anti-diabetic therapy. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4544143/ /pubmed/26312005 http://dx.doi.org/10.4103/0976-500X.162016 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Sahoo, Jayaprakash Kamalanathan, Sadishkumar Vivekanandan, Muthupillai Swaminathan, Rathinam Palamalai Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy |
title | Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy |
title_full | Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy |
title_fullStr | Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy |
title_full_unstemmed | Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy |
title_short | Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy |
title_sort | acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544143/ https://www.ncbi.nlm.nih.gov/pubmed/26312005 http://dx.doi.org/10.4103/0976-500X.162016 |
work_keys_str_mv | AT sahoojayaprakash acalculouspyelonephritisandcholecystitisoccurringsimultaneouslyinadiabeticpatientonsitagliptintherapy AT kamalanathansadishkumar acalculouspyelonephritisandcholecystitisoccurringsimultaneouslyinadiabeticpatientonsitagliptintherapy AT vivekanandanmuthupillai acalculouspyelonephritisandcholecystitisoccurringsimultaneouslyinadiabeticpatientonsitagliptintherapy AT swaminathanrathinampalamalai acalculouspyelonephritisandcholecystitisoccurringsimultaneouslyinadiabeticpatientonsitagliptintherapy |